Actively Recruiting
Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation
Led by Children's Hospital of Eastern Ontario · Updated on 2024-06-05
20
Participants Needed
1
Research Sites
23 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Approximately 20% of Canadian adolescents experience thoughts of suicide, or suicidal ideation (SI), and suicide is the second leading cause of death among Canadians aged 15-19 years. The emergency department at CHEO sees approximately four patients per day with SI. Even though this is a medical emergency, there are no fast-acting treatments available. Ketamine is a medication that is commonly used to safely sedate children who require painful procedures in the emergency department. For nearly ten years, intravenous ketamine has also been shown to rapidly reduce SI in adults. However, ketamine as a treatment for SI has never been studied in adolescents. The primary study objective is to pilot a clinical trial that investigates intravenous ketamine to emergently treat SI in adolescents. If intravenous ketamine can relieve symptoms of SI for youth, this would have tremendous effects on patients and would dramatically change how physicians treat adolescent mental health emergencies. If ketamine is effective for several weeks, as it is in adults, it will help temporize patients until they receive more long-term psychiatric care. At the system level, it has the potential to reduce emergency visits and lengthy admissions. The investigators feel that the results of this study will be generalizable to pediatric centres across Canada and beyond.
CONDITIONS
Official Title
Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Responds "yes" to Ask Suicide Screening Question (ASQ) #5 asking if they are having thoughts of killing themselves right now
- Moderate to severe suicidal ideation, defined as a score 3 on the first 5 questions of the Beck Scale for Suicidal Ideation (SSI5)
- Age 12 to 17 years, inclusive
- Medically cleared by treating physician, with no serious physical injury or acute ingestion requiring urgent intervention or monitoring
You will not qualify if you...
- Acute intoxication from any substance including alcohol
- Previously or currently enrolled in this or another clinical trial
- History of intellectual disability or autism spectrum disorder
- Active or past psychosis or psychotic disorder
- History of non-psychiatric neurological disorders such as epilepsy
- Contraindications to ketamine including allergy, cerebrovascular disease, elevated intracranial pressure, severe hypertension, or severe cardiac problems
- On an involuntary psychiatric hold
- Requires physical or chemical restraint
- History of violence while in hospital
- Pregnant or breastfeeding
- Received opioids within 2 hours prior to study screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital Of Eastern Ontario
Ottawa, Ontario, Canada, K1H 8L1
Actively Recruiting
Research Team
M
Maala Bhatt, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here